Radiology and Oncology最新文献

{"title":"Phase angle as a prognostic indicator of surgical outcomes in patients with gastrointestinal cancer.","authors":"Jana Gulin, Ester Ipavic, Denis Mlakar Mastnak, Erik Brecelj, Ibrahim Edhemovic, Nada Rotovnik Kozjek","doi":"10.2478/raon-2023-0060","DOIUrl":"10.2478/raon-2023-0060","url":null,"abstract":"<p><strong>Background: </strong>In patients with gastrointestinal cancer with planned elective surgery, malnutrition increases the risk of adverse outcomes in the postoperative period. The phase angle, measured by the bioelectrical impedance analysis is an indicator of the metabolic and functional status of the patient. It may be an important prognostic indicator for the clinical outcome of post-surgical treatment in patients with gastrointestinal cancer.</p><p><strong>Patients and methods: </strong>In this prospective study, 70 patients with gastrointestinal cancer had their phase angles measured by the bioelectrical impedance analysis before the surgery. During the first month after the surgery, we documented the postoperative complications from the patient's records and classified them according to the Clavien Dindo classification of surgical complications. The time of hospitalization was also recorded. The data was statistically analysed in SPSS.</p><p><strong>Results: </strong>We found a statistically significant difference (p = 0.036) in the average value of phase angles between the group of patients who had postoperative complications (phase angle 5.09°) and the group without postoperative complications (5.64°). We noted a correlating trend of decreasing phase angle values and increasing hospitalization time (Pe R = -0,40, p = 0,001). The phase angle cut-off value (5.5°) was calculated using the ROC curve method, predicting a higher risk of the postoperative complications (p = 0,037) in patients with lower phase angle.</p><p><strong>Conclusions: </strong>Lower phase angle values before surgery were associated with more complications during the first month after surgery and longer hospitalization time. We found that a phase angle below than 5.5° could serve as a marker that predicts a greater risk of postoperative complications.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 4","pages":"524-529"},"PeriodicalIF":2.4,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138462349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma.","authors":"Simona Miceska, Erik Skof, Simon Bucek, Cvetka Grasic Kuhar, Gorana Gasljevic, Spela Smrkolj, Veronika Kloboves Prevodnik","doi":"10.2478/raon-2023-0046","DOIUrl":"10.2478/raon-2023-0046","url":null,"abstract":"<p><strong>Background: </strong>High-grade serous carcinoma (HGSC) is often associated with ascites at presentation. Our objective was to quantify immune cells (ICs) in ascites prior to any treatment was given and evaluate their impact on progression-free survival (PFS) and overall survival (OS).</p><p><strong>Patients and methods: </strong>Forty-seven patients with primary HGSC and ascites were included. Flow-cytometric analysis was performed to detect percentages of CD3⁺ T cells (CD4⁺, CD8⁺, Tregs, and NKT cells), B cells, NK cells (CD56^brightCD16^- and CD56^dimCD16⁺ subsets), macrophages and dendritic cells (DCs). Furthermore, CD103 expression was analyzed on T cells and their subsets, while PD-1 and PD-L1 expression on all ICs. Cut-off of low and high percentages of ICs was determined by the median of variables, and correlation with PFS and OS was calculated.</p><p><strong>Results: </strong>CD3⁺ cells were the predominant ICs (median 51%), while the presence of other ICs was much lower (median ≤10%). CD103⁺ expression was mostly present on CD8⁺, and not CD4⁺ cells. PD-1 was mainly expressed on CD3⁺ T cells (median 20%), lower expression was observed on other ICs (median ≤10%). PD-L1 expression was not detected. High percentages of CD103⁺CD3⁺ T cells, PD-1⁺ Tregs, CD56^brightCD16^- NK cells, and DCs correlated with prolonged PFS and OS, while high percentages of CD8⁺ cells, macrophages, and PD-1⁺CD56^brightCD16^- NK cells, along with low percentages of CD4⁺ cells, correlated with better OS only. DCs were the only independent prognostic marker among all ICs.</p><p><strong>Conclusions: </strong>Our results highlight the potential of ascites tumor-immune microenvironment to provide additional prognostic information for HGSC patients. However, a larger patient cohort and longer follow-up are needed to confirm our findings.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 4","pages":"493-506"},"PeriodicalIF":2.4,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138462354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of normobaric and hyperbaric oxygenation on MRI signal intensities in <i>T₁</i> -weighted, <i>T₂</i> -weighted and FLAIR images in human brain.","authors":"Vida Velej, Ksenija Cankar, Jernej Vidmar","doi":"10.2478/raon-2023-0043","DOIUrl":"10.2478/raon-2023-0043","url":null,"abstract":"<p><strong>Background: </strong>Dissolved oxygen has known paramagnetic effects in magnetic resonance imaging (MRI). The aim of this study was to compare the effects of normobaric oxygenation (NBO) and hyperbaric oxygenation (HBO) on human brain MRI signal intensities.</p><p><strong>Patients and methods: </strong>Baseline brain MRI was performed in 17 healthy subjects (mean age 27.8 ± 3.2). MRI was repeated after exposure to the NBO and HBO at different time points (0 min, 25 min, 50 min). Signal intensities in <i>T</i> ₁-weighted, <i>T</i> ₂-weighted images and fluid attenuated inversion recovery (FLAIR) signal intensities of several intracranial structures were compared between NBO and HBO.</p><p><strong>Results: </strong>Increased <i>T</i> ₁-weighted signal intensities were observed in white and deep grey brain matter, cerebrospinal fluid (CSF), venous blood and vitreous body after exposure to NBO as well as to HBO compared to baseline (Dunnett's test, <i>p</i> < 0.05) without significant differences between both protocols. There was also no significant difference in <i>T</i> ₂-weighted signal intensities between NBO and HBO. FLAIR signal intensities were increased only in the vitreous body after NBO and HBO and FLAIR signal of caudate nucleus was decreased after NBO (Dunnett's test, <i>p</i> < 0.05). The statistically significant differences in FLAIR signal intensities were found between NBO and HBO (paired t-test, <i>p</i> < 0.05) in most observed brain structures (paired t-test, <i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Our results show that NBO and HBO alters signal intensities <i>T</i> ₁-weighted and FLAIR images of human brain. The differences between NBO and HBO are most pronounced in FLAIR imaging.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 3","pages":"317-324"},"PeriodicalIF":2.4,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10227316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer risk assessment and risk distribution in 3,491 Slovenian women invited for screening at the age of 50; a population-based cross-sectional study.","authors":"Katja Jarm, Vesna Zadnik, Mojca Birk, Milos Vrhovec, Kristijana Hertl, Zan Klanecek, Andrej Studen, Cveto Sval, Mateja Krajc","doi":"10.2478/raon-2023-0039","DOIUrl":"10.2478/raon-2023-0039","url":null,"abstract":"<p><strong>Background: </strong>The evidence shows that risk-based strategy could be implemented to avoid unnecessary harm in mammography screening for breast cancer (BC) using age-only criterium. Our study aimed at identifying the uptake of Slovenian women to the BC risk assessment invitation and assessing the number of screening mammographies in case of risk-based screening.</p><p><strong>Patients and methods: </strong>A cross-sectional population-based study enrolled 11,898 women at the age of 50, invited to BC screening. The data on BC risk factors, including breast density from the first 3,491 study responders was collected and BC risk was assessed using the Tyrer-Cuzick algorithm (version 8) to classify women into risk groups (low, population, moderately increased, and high risk group). The number of screening mammographies according to risk stratification was simulated.</p><p><strong>Results: </strong>57% (6,785) of women returned BC risk questionnaires. When stratifying 3,491 women into risk groups, 34.0% were assessed with low, 62.2% with population, 3.4% with moderately increased, and 0.4% with high 10-year BC risk. In the case of potential personalised screening, the number of screening mammographies would drop by 38.6% compared to the current screening policy.</p><p><strong>Conclusions: </strong>The study uptake showed the feasibility of risk assessment when inviting women to regular BC screening. 3.8% of Slovenian women were recognised with higher than population 10-year BC risk. According to Slovenian BC guidelines they may be screened more often. Overall, personalised screening would decrease the number of screening mammographies in Slovenia. This information is to be considered when planning the pilot and assessing the feasibility of implementing population risk-based screening.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 3","pages":"337-347"},"PeriodicalIF":2.4,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10231232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central and peripheral pulmonary sclerosing pneumocytomas: multi-phase CT study and comparison with Ki-67.","authors":"Yanli Zhang, Chao Ran, Wei Li","doi":"10.2478/raon-2023-0042","DOIUrl":"10.2478/raon-2023-0042","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the multi-phase CT findings of central and peripheral pulmonary sclerosing pneumocytomas (PSPs) and compared them with Ki-67 to reveal their neoplastic nature.</p><p><strong>Patients and methods: </strong>Multi-phase CT and clinical data of 33 PSPs (15 central PSPs and 18 peripheral PSPs) were retrospectively analyzed and compared their multi-phase CT features and Ki-67 levels.</p><p><strong>Results: </strong>For quantitative indicators, central PSPs were larger than peripheral PSPs (10.39 ± 3.25 cm³ <i>vs.</i> 4.65 ± 2.61 cm³, P = 0.013), and tumor size was negatively correlated with acceleration index (r = -0.845, P < 0.001). The peak enhancement of central PSPs appeared in the delayed phase, with a longer time to peak enhancement (TTP, 100.81 ± 19.01 s), lower acceleration index (0.63 ± 0.17), progressive enhancement, and higher Ki-67 level. The peak enhancement of peripheral PSPs appeared in the venous phase, with the shorter TTP (62.67 ± 20.96 s, P < 0.001), higher acceleration index (0.99 ± 0.25, P < 0.001), enhancement washout, and lower Ki-67 level. For qualitative indicators, the overlying vessel sign (86.67% <i>vs.</i> 44.44%, P = 0.027), prominent pulmonary artery sign (73.33% <i>vs.</i> 27.78%, P = 0.015), and obstructive inflammation/atelectasis (26.67% <i>vs.</i> 0%, P = 0.033) were more common in central PSPs, while peripheral PSPs were more common with halo sign (38.89% <i>vs.</i> 6.67%, P = 0.046).</p><p><strong>Conclusions: </strong>The location of PSP is a possible contributing factor to its diverse imaging-pathological findings. The tumor size, multi-phase enhancement, qualitative signs, and Ki-67 were different between central and peripheral PSPs. Combined tumor size, multi-phase findings, and Ki-67 level are helpful to reveal the nature of the borderline tumor.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 3","pages":"310-316"},"PeriodicalIF":2.4,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10227315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights.","authors":"Xing Li, Kaida Liu, Lidong Xing, Boris Rubinsky","doi":"10.2478/raon-2023-0044","DOIUrl":"10.2478/raon-2023-0044","url":null,"abstract":"<p><strong>Background: </strong>Tumor Treating Fields (TTFields) is a non-invasive modality for cancer treatment that utilizes a specific sinusoidal electric field ranging from 100 kHz to 300 kHz, with an intensity of 1 V/cm to 3 V/cm. Its purpose is to inhibit cancer cell proliferation and induce cell death. Despite promising outcomes from clinical trials, TTFields have received FDA approval for the treatment of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM). Nevertheless, global acceptance of TTFields remains limited. To enhance its clinical application in other types of cancer and gain a better understanding of its mechanisms of action, this review aims to summarize the current research status by examining existing literature on TTFields' clinical trials and mechanism studies.</p><p><strong>Conclusions: </strong>Through this comprehensive review, we seek to stimulate novel ideas and provide physicians, patients, and researchers with a better comprehension of the development of TTFields and its potential applications in cancer treatment.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 3","pages":"279-291"},"PeriodicalIF":2.4,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10283655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.","authors":"Lidija Ljubicic, Urska Janzic, Mojca Unk, Ana Sophie Terglav, Katja Mohorcic, Fran Seiwerth, Lela Bitar, Sonja Badovinac, Sanja Plestina, Marta Korsic, Suzana Kukulj, Miroslav Samarzija, Marko Jakopovic","doi":"10.2478/raon-2023-0040","DOIUrl":"10.2478/raon-2023-0040","url":null,"abstract":"<p><strong>Background: </strong>The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy with immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +/- ChT remains an open question, and docetaxel plus nintedanib represent a valid second line option.</p><p><strong>Patients and methods: </strong>A multicenter retrospective trial of real-life treatment patterns and outcomes of patients with advanced lung adenocarcinoma treated with docetaxel plus nintedanib after the failure of ICI and/or ChT was performed. Patients from 2 Slovenian and 1 Croatian oncological center treated between June 2014 and August 2022 were enrolled. We assessed objective response (ORR), disease control rate (DCR), median progression free survival (PFS), median overall survival (OS), and safety profile of treatment.</p><p><strong>Results: </strong>There were 96 patients included in the analysis, with ORR of 18.8%, DCR of 57.3%, median PFS of 3.0 months (95% CI: 3.0-5.0 months), and a median OS of 8.0 months (95% CI: 7.0-10.0 months). The majority of patients (n = 47,49%) received docetaxel plus nintedanib as third-line therapy. The ORR for this subset of patients was 19.1%, with a DCR of 57.4%. The highest response rate was observed in patients who received second-line docetaxel plus nintedanib after first-line combination of ChT-ICI therapy (n = 24), with an ORR of 29.2% and DCR of 66.7% and median PFS of 4.0 months (95% CI: 3.0-8.0 months). Fifty-three patients (55.2%) experienced adverse events (AEs), most frequently gastrointestinal; diarrhea (n = 29, 30.2%), and increased liver enzyme levels (n = 17, 17.7%).</p><p><strong>Conclusions: </strong>The combination of docetaxel and nintedanib can be considered an effective therapy option with an acceptable toxicity profile for patients with advanced NSCLC after the failure of ICI +/- ChT.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 3","pages":"397-404"},"PeriodicalIF":2.4,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10232747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prominin 2 decreases cisplatin sensitivity in non-small cell lung cancer and is modulated by CTCC binding factor.","authors":"Jiyang Tang, Dejun Shu, Zhimin Fang, Gaolan Yang","doi":"10.2478/raon-2023-0033","DOIUrl":"10.2478/raon-2023-0033","url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) is the major pathological type of lung cancer and accounts for the majority of lung cancer-related deaths worldwide. We investigated the molecular mechanism of prominin 2 (PROM2) involved in cisplatin resistance in NSCLC.</p><p><strong>Patients and methods: </strong>The GEO database was analyzed to obtain differential genes to target PROM2. Immunohistochemistry and western blotting were used to detect protein expression levels. To examine the role of PROM2 in NSCLC, we overexpressed or knocked down PROM2 by transfection of plasmid or small interfering RNA. In functional experiments, CCK8 was used to detect cell viability. Cell migration and invasion and apoptosis were detected by transwell assay and flow cytometry, respectively. Mechanistically, the regulation of PROM2 by CTCF was detected by ChIP-PCR. <i>In vivo</i> experiments confirmed the role of PROM2 in NSCLC.</p><p><strong>Results: </strong>GEO data analysis revealed that PROM2 was up-regulated in NSCLC, but its role in NSCLC remains unclear. Our clinical samples confirmed that the expression of PROM2 was markedly increased in NSCLC tissue. Functionally, Overexpression of PROM2 promotes cell proliferation, migration and invasion, and cisplatin resistance. CTCF up-regulates PROM2 expression by binding to its promoter region. <i>In vivo</i> experiments confirmed that PROM2 knockdown could inhibit tumor growth and increase the sensitivity of tumor cells to cisplatin.</p><p><strong>Conclusions: </strong>PROM2 up-regulation in NSCLC can attenuate the sensitivity of NSCLC cells to cisplatin and promote the proliferation, migration and invasion of tumor cells. PROM2 may provide a new target for the treatment of NSCLC.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 3","pages":"325-336"},"PeriodicalIF":2.4,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10220502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment and outcome of patients with Graves' disease and metastatic differentiated thyroid cancer.","authors":"Nikola Besic, Barbara Vidergar-Kralj","doi":"10.2478/raon-2023-0034","DOIUrl":"10.2478/raon-2023-0034","url":null,"abstract":"<p><strong>Background: </strong>The aim of the study was to report on the experience in a single tertiary cancer center about the treatment and outcome of patients with Graves' disease (GD) and metastatic thyroid cancer as compared with patients without GD in our country.</p><p><strong>Patients and methods: </strong>Altogether, 28 patients (8 males, 20 females; 49-85 years of age; median 74 years) were treated because of differentiated thyroid cancer and distant metastasis at the time of diagnosis during a 10-year period (from 2010 to 2019) in the Republic of Slovenia. The subject of our retrospective study were four patients (three men, one female; 64-76 years of age, median 73 years) who had Graves' disease and metastatic thyroid cancer.</p><p><strong>Results: </strong>The mean age of patients without GD and with GD was 74 years and 71 years, respectively (p = 0.36). There was a trend for male predominance in patients with GD (p = 0.06). There was no statistical difference in size of primary tumors, pT stage or pN stage between the group of patients without GD and with GD. The median length of follow-up was 3.33 years (range 0.04-7.83) and 5-year disease-specific survival was 51%. One of four patients with GD and 14 of 24 patients without GD died of thyroid cancer. There was no statistical difference in disease-specific survival between patients' group of without GD and with GD (p = 0.59).</p><p><strong>Conclusions: </strong>In our country Slovenia, 14% of patients with metastatic differentiated thyroid carcinoma at the time of diagnosis had Graves' disease. There was no difference in the treatment, outcome or survival of patients with GD in comparison to those without GD.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 3","pages":"380-388"},"PeriodicalIF":2.4,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10283657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Billroth-I anastomosis in distal subtotal gastrectomy for non-early gastric adenocarcinoma.","authors":"Sevak S Shahbazyan, Mushegh A Sahakyan, Artak Gabrielyan, Xiaoran Lai, Aram Martirosyan, Hmayak Petrosyan, Shushan Yesayan, Artur M Sahakyan","doi":"10.2478/raon-2023-0041","DOIUrl":"10.2478/raon-2023-0041","url":null,"abstract":"<p><strong>Background: </strong>Billroth-I (B-I) anastomosis is known as a simple and physiological reconstruction method after distal subtotal gastrectomy for early gastric cancer. Yet its role and oncological validity in non-early gastric adenocarcinoma (NEGA) remain unclear.</p><p><strong>Patients and methods: </strong>Patients with NEGA without distant metastases operated between May 2004 and December 2020 were included. Surgical and oncologic outcomes of distal subtotal gastrectomy were studied in patients with B-I and Billroth II (B-II) anastomoses. Propensity score matching (PSM) was used to adjust for age, gender, tumor size, location, resection type, pT and pN stages.</p><p><strong>Results: </strong>A total number of 332 patients underwent distal subtotal gastrectomy for NEGA followed by B-I and B-II anastomoses in 165 (49.7%) and 167 (50.3%) cases, respectively. B-I was applied in patients with smaller tumor size, less advanced pT stage and tumor location in the gastric antrum. The former was also associated with lower proportion of multiorgan resections and shorter operative time. After PSM, these differences became statistically non-significant, except operative time. Postoperative outcomes were similar before and after PSM. Greater lymph node yield was observed in patients with B-I anastomosis. The incidence of recurrence, specifically local recurrence was lower in patients with B-I anastomosis. However, this association was not statistically significant in the multivariable model. Median overall survival was 38 months, without significant differences between the groups.</p><p><strong>Conclusions: </strong>The use of B-I anastomosis after distal subtotal gastrectomy for NEGA is associated with satisfactory surgical and oncologic outcomes. B-I anastomosis should be considered as a valid reconstruction method in these patients.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 3","pages":"356-363"},"PeriodicalIF":2.4,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10283658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}